NasdaqGM:HROWPharmaceuticals
Harrow (HROW) Is Up 9.7% After Return to Profitability and Expanded Coverage for VEVYE – What's Changed
Harrow Inc. recently reported third quarter 2025 results, with revenue rising to US$71.64 million from US$49.26 million a year earlier, and net income improving from a US$4.22 million loss to a US$1.02 million profit.
The company emphasized strong uptake in key products like VEVYE and IHEEZO, launch momentum for TRIESENCE, and expanded insurance coverage, pointing to initiatives aimed at longer-term growth.
We’ll consider how the return to profitability and new insurance coverage for VEVYE...